These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27084683)

  • 21. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
    Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
    Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA; Segal SV; Méndez JH
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
    Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
    Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
    Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
    Michaeli DT; Stoycheva S; Marcus SM; Zhang W; Michaeli JC; Michaeli T
    Clin Drug Investig; 2022 Apr; 42(4):333-343. PubMed ID: 35294726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A; Ovcinnikova O; Palmer C; Engelbrecht K; Reuschenbach M; Daniels V
    JAMA Netw Open; 2024 Oct; 7(10):e2437703. PubMed ID: 39365579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
    Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
    PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.